Basilea buys rights to fosmanogepix, a broad-spectrum antifungal

14 November 2023

Swiss drugmaker Basilea Pharmaceutica (SIX: BSLN) has entered into an asset purchase agreement with Amplyx Pharmaceuticals, which was bought in 2021 by US pharma giant Pfizer (NYSE: PFE), to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate.

In addition, Basilea has acquired the rights to a pre-clinical antifungal compound, with the two candidates adding to Basilea’s acquisition of rights to Gravitas Therapeutics’ GR-2397, also a clinical-stage antifungal compound

Fosmanogepix is a potential first-in-class antifungal treatment candidate with a novel mechanism of action. It is available in intravenous and oral formulations and has been evaluated for efficacy and safety in a Phase I/I program, including three open-label Phase II studies for the treatment of Candidemia, including Candida auris, and invasive mold infections.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK